
    
      CF patients often have lung infections. Pseudomonas aeruginosa (Pa) is the most significant
      bacteria in CF, with up to 80% of CF patients eventually becoming infected. These patients
      are often treated with antibiotics with variable results. This study will examine the impact
      of a single-dose of an investigational drug, KB001, on Pa bacteria in the CF lung.
    
  